XML 22 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue
 6 Months Ended
Jun. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Net product revenue
$
5,168.7

 
$
5,129.4

 
$
9,861.0

 
$
9,735.3

Collaboration and other revenue (1)
468.0

 
455.6

 
867.9

 
813.5

Revenue
$
5,636.7

 
$
5,585.0

 
$
10,728.9

 
$
10,548.8

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $59.6 million and $95.1 million during the three and six months ended June 30, 2019, respectively, and $133.6 million and $183.7 million during the three and six months ended June 30, 2018, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta® and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Disaggregation of Revenue
The following table summarizes revenue by product:
 
Three Months Ended
June 30,
 
2019
 
2018
 
United States (U.S.) (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity®
$
792.1

$
236.4

$
1,028.5

 
$
612.4

$
167.4

$
779.8

Humalog® (2)
396.1

281.5

677.6

 
464.5

305.2

769.8

Forteo®
172.8

188.0

360.8

 
225.1

209.4

434.5

Humulin®
220.1

102.6

322.6

 
238.8

107.2

346.0

Basaglar®
232.2

58.6

290.7

 
156.5

45.3

201.8

Jardiance (3)
142.6

89.3

231.9

 
85.6

61.6

147.2

Trajenta (4)
64.5

89.5

153.9

 
56.8

84.9

141.7

Other Endocrinology
81.6

59.3

141.2

 
61.5

72.8

134.1

Total Endocrinology
2,102.0

1,105.2

3,207.2

 
1,901.2

1,053.8

2,954.9

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta®
341.7

236.1

577.8

 
281.3

274.6

555.9

Cyramza®
89.8

152.0

241.8

 
75.4

143.3

218.8

Erbitux®
136.9

22.4

159.3

 
140.0

26.4

166.4

Verzenio®
105.2

28.7

133.9

 
57.7

—

57.7

Other Oncology
16.2

68.2

84.4

 
56.7

54.7

111.3

Total Oncology
689.8

507.4

1,197.2

 
611.1

499.0

1,110.1

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta®
18.1

169.0

187.2

 
12.6

169.4

181.9

Zyprexa®
9.3

95.1

104.3

 
11.8

116.2

128.0

Strattera®
21.2

61.4

82.6

 
16.9

97.3

114.2

Emgality®
33.8

0.5

34.3

 
—

—

—

Other Neuroscience
22.0

22.3

44.3

 
24.3

22.4

46.9

Total Neuroscience
104.4

348.3

452.7

 
65.6

405.3

471.0

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
268.1

85.7

353.8

 
173.6

46.5

220.1

Olumiant®
10.7

91.7

102.4

 
1.7

42.9

44.7

Total Immunology
278.8

177.3

456.1

 
175.3

89.4

264.7

 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
Cialis®
35.1

165.1

200.2

 
345.7

193.0

538.7

Other
42.4

80.8

123.3

 
143.4

102.2

245.6

Total Other
77.5

245.9

323.5

 
489.1

295.2

784.3

Revenue
$
3,252.5

$
2,384.2

$
5,636.7

 
$
3,242.3

$
2,342.7

$
5,585.0

Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Humalog revenue includes Insulin Lispro.
(3) Jardiance revenue includes Glyxambi® and Synjardy®.
(4) Trajenta revenue includes Jentadueto®.


 
Six Months Ended
June 30,
 
2019
 
2018
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity
$
1,457.7

$
450.6

$
1,908.3

 
$
1,140.6

$
317.5

$
1,458.1

Humalog (2)
844.8

563.7

1,408.4

 
968.7

592.8

1,561.5

Forteo
298.7

375.0

673.7

 
347.2

400.5

747.8

Humulin
421.3

199.0

620.3

 
460.4

211.5

671.9

Basaglar
430.3

111.8

542.1

 
283.2

84.6

367.8

Jardiance (3)
267.8

167.7

435.5

 
180.6

117.6

298.2

Trajenta (4)
111.8

174.0

285.9

 
110.9

171.9

282.8

Other Endocrinology
143.5

119.6

263.1

 
125.4

140.2

265.6

Total Endocrinology
3,975.9

2,161.4

6,137.3

 
3,617.0

2,036.6

5,653.7

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
623.5

453.5

1,076.9

 
526.7

528.9

1,055.5

Cyramza
164.9

275.2

440.0

 
143.7

258.7

402.4

Erbitux
250.3

27.5

277.7

 
261.3

54.7

316.1

Verzenio
198.7

44.6

243.3

 
87.4

—

87.4

Other Oncology
46.3

125.5

172.1

 
102.3

103.0

205.3

Total Oncology
1,283.7

926.3

2,210.0

 
1,121.4

945.3

2,066.7

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
28.4

322.9

351.3

 
24.8

326.7

351.5

Zyprexa
18.6

193.0

211.5

 
20.6

230.0

250.6

Strattera
22.7

126.1

148.8

 
63.9

181.0

244.9

Emgality
46.0

2.6

48.5

 
—

—

—

Other Neuroscience
39.8

45.7

85.8

 
48.5

48.2

96.7

Total Neuroscience
155.5

690.3

845.9

 
157.8

785.9

943.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz
449.0

157.4

606.3

 
284.7

81.8

366.5

Olumiant
17.1

167.4

184.5

 
1.7

75.2

76.9

Total Immunology
466.0

324.8

790.8

 
286.5

157.0

443.4

 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
Cialis
178.4

330.0

508.4

 
659.1

375.0

1,034.1

Other
83.8

152.8

236.5

 
196.1

211.1

407.2

Total Other
262.2

482.9

744.9

 
855.2

586.1

1,441.3

Revenue
$
6,143.3

$
4,585.6

$
10,728.9

 
$
6,037.9

$
4,510.9

$
10,548.8

Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Humalog revenue includes Insulin Lispro.
(3) Jardiance revenue includes Glyxambi and Synjardy.
(4) Trajenta revenue includes Jentadueto.




The following table summarizes revenue by geographical area:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Revenue—to unaffiliated customers (1):
 
 
 
 
 
 
 
United States (2)
$
3,252.5

 
$
3,242.3

 
$
6,143.3

 
$
6,037.9

Europe
928.2

 
941.0

 
1,828.5

 
1,834.8

Japan
653.2

 
640.4

 
1,196.9

 
1,177.2

Other foreign countries
802.8

 
761.2

 
1,560.2

 
1,498.8

Revenue
$
5,636.7

 
$
5,585.0

 
$
10,728.9

 
$
10,548.8

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
(2) U.S. revenue includes revenue in Puerto Rico.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 4 percent and 3 percent of U.S. revenue during the three and six months ended June 30, 2019, respectively, and approximately 1 percent and 2 percent of U.S. revenue during the three and six months ended June 30, 2018, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 
June 30, 2019
 
December 31, 2018
Contract liabilities
$
277.6

 
$
294.9


Revenue recognized from contract liabilities during the three and six months ended June 30, 2019 and 2018 was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.